IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+12.69%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$269M
AUM Growth
+$269M
(-5%)
Cap. Flow
+$21.1M
Cap. Flow
% of AUM
7.85%
Top 10 Holdings %
Top 10 Hldgs %
54.13%
Holding
130
New
23
Increased
25
Reduced
23
Closed
23
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$15.8M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$13.4M |
| 3 |
Immunovant
IMVT
|
$11.4M |
| 4 |
Akero Therapeutics
AKRO
|
$10.1M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$9.45M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$12.2M |
| 2 |
Merck
MRK
|
$11.5M |
| 3 |
Biohaven
BHVN
|
$8.36M |
| 4 |
Insmed
INSM
|
$8.34M |
| 5 |
IDEAYA Biosciences
IDYA
|
$7.39M |
Sector Composition
| 1 | Healthcare | 97.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Tyra Biosciences
TYRA
$657M
| $663K | 0.08% |
48,170
| – | – |
|
52
Immunic
IMUX
$79.4M
| $662K | 0.08% |
450,000
-200,000
| -31% | -$294K |
|
53
Eli Lilly
LLY
$661B
| $659K | 0.08% |
+1,227
| New | +$659K |
|
54
ProQR Therapeutics
PRQR
$256M
| $614K | 0.07% |
472,625
| – | – |
|
|
AUTL
55
Autolus Therapeutics
AUTL
$383M
| $612K | 0.07% |
262,694
+2,607
| +1% | +$6.07K |
|
56
Cogent Biosciences
COGT
$1.83B
| $612K | 0.07% |
62,766
| – | – |
|
57
Immatics
IMTX
$662M
| $568K | 0.07% |
49,031
| – | – |
|
58
Kodiak Sciences
KOD
$453M
| $563K | 0.07% |
312,881
+250,354
| +400% | +$451K |
|
59
Karyopharm Therapeutics
KPTI
$61.4M
| $536K | 0.06% |
26,667
| – | – |
|
60
Anebulo Pharmaceuticals
ANEB
$101M
| $504K | 0.06% |
157,862
+1,659
| +1% | +$5.29K |
|
|
TCON
61
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $492K | 0.06% |
138,277
| – | – |
|
|
HOOK
62
DELISTED
HOOKIPA Pharma
HOOK
| $327K | 0.04% |
53,078
-6,922
| -12% | -$42.6K |
|
63
Protara Therapeutics
TARA
$125M
| $315K | 0.04% |
188,664
| – | – |
|
64
TG Therapeutics
TGTX
$5.03B
| $272K | 0.03% |
+32,547
| New | +$272K |
|
65
PTC Therapeutics
PTCT
$4.41B
| $243K | 0.03% |
+10,862
| New | +$243K |
|
|
VRNA
66
Verona Pharma
VRNA
$9.18B
| $214K | 0.03% |
318,591
+4,914
| +2% | +$3.3K |
|
|
MREO
67
Mereo BioPharma
MREO
$275M
| $191K | 0.02% |
591,676
-300,000
| -34% | -$97K |
|
|
CMMB
68
Chemomab Therapeutics
CMMB
$15.7M
| $191K | 0.02% |
53,348
| – | – |
|
69
scPharmaceuticals
SCPH
$296M
| $133K | 0.02% |
18,647
-131,353
| -88% | -$935K |
|
70
Relmada Therapeutics
RLMD
$48.8M
| $121K | 0.01% |
40,369
-25,122
| -38% | -$75.4K |
|
71
Foghorn Therapeutics
FHTX
$298M
| $76.5K | 0.01% |
15,292
+292
| +2% | +$1.46K |
|
72
Ocular Therapeutix
OCUL
$2.25B
| $67.8K | 0.01% |
21,590
-78,410
| -78% | -$246K |
|
73
Syndax Pharmaceuticals
SNDX
$1.39B
| $58.1K | 0.01% |
+4,000
| New | +$58.1K |
|
74
Synlogic
SYBX
$17.4M
| $57.5K | 0.01% |
20,448
-2
| -0% | -$6 |
|
75
Stoke Therapeutics
STOK
$1.08B
| $47.7K | 0.01% |
12,116
-58,274
| -83% | -$230K |
|